Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of 18 weeks of TAC chemotherapy on skeletal muscle composition in women with breast cancer
NL-OMON25768Withdrawn
- Sponsor
- Máxima Medisch Centrum
- Start
- May 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel, doxorubicin and cyclophosphamide in breast cancer, sponsored by Máxima Medisch Centrum. Primary endpoint: Skeletal muscle composition and metabolism in vastus lateralis biopsy. Planned start May 2012; status: withdrawn.
02
Drugs
docetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON25768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25768.